Neurent Medical Raises $74M in Series C Round to Commercialize Chronic Rhinitis Device

Why It Matters

The funding positions Neurent to scale a proven, minimally invasive therapy for a condition affecting 25 % of adults, potentially reshaping the rhinitis treatment landscape and generating sizable revenue streams.

Key Takeaways

• €62.5M Series C funding fuels global rollout
• FDA cleared Neuromark uses low‑power radiofrequency
• 55% symptom reduction shown in two‑year study
• Reimbursement codes secured with Cigna, UnitedHealthcare
• Chronic rhinitis impacts one in four adults globally

Pulse Analysis

Chronic rhinitis, affecting roughly one in four adults, remains a therapeutic blind spot despite its prevalence and impact on quality of life. Traditional pharmacologic options often provide incomplete relief and can carry side‑effects, prompting clinicians to seek device‑based alternatives. Neuromark’s low‑power radiofrequency technology creates precise lesions in the nasal mucosa, attenuating parasympathetic signaling that drives mucus overproduction. Clinical data show a 55 % drop in the Total Nasal Symptom Score, with improvements across congestion, rhinorrhea, sneezing and itching, positioning the device as a compelling non‑drug solution.

The €62.5 million Series C injection, led by MVM Partners and Sofinnova Partners, underscores growing investor confidence in med‑tech platforms that combine clear regulatory pathways with scalable reimbursement models. Prior FDA 510(k) clearances in 2021, 2022 and 2025 have de‑risked the product’s market entry, while the involvement of established life‑science backers such as EQT Life Sciences and Atlantic Bridge provides strategic guidance for global distribution. This capital will fund sales force expansion, manufacturing capacity, and next‑generation device refinements, accelerating Neuromark’s penetration beyond its current European stronghold into the U.S. and Asian markets.

Securing reimbursement codes from Cigna and UnitedHealthcare in late 2025 removed a critical barrier, allowing providers to bill the procedure without experimental designations. As payers recognize the cost‑saving potential of reducing chronic medication use and downstream complications, broader coverage is likely to follow, driving volume growth. For patients, wider access translates into faster symptom relief and fewer missed workdays, while health systems stand to benefit from lower overall treatment expenditures. The convergence of clinical efficacy, regulatory clearance, financing, and payer acceptance positions Neuromark to become a standard of care for chronic rhinitis.

Deal Summary

Neurent Medical announced a €62.5 million ($74 million) Series C financing to accelerate commercialization of its Neuromark radio‑frequency device for chronic rhinitis. The round was led by MVM Partners with participation from Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland.